Perbandingan kadar sitokin interleukin-17 dalam serum antara penderita dengan bukan penderita psoriasis vulgaris
DAFTAR PUSTAKA
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
MacDonald A, Burden AD. Psoriasis: advances in pathophysiology and
management. Postgrad Med J. 2007(83): 690-7.
Neimann AL, Porter SB, Gelfand JM. The epidemiology of psoriasis.
Expert Rev. Dermatol. 2006(1): 63-75.
Gudjonsson JE, Johnston A, Sigmundsdottir H, Valdimarsson H.
Immunopathogenic mechanism in psoriasis. Clin Exp Immunol.
2004(135):1-8.
Lowes MA, Lew W, Krueger JG. Current concepts in the
immunopathogenesis of psoriasis. Dermatol Clin.2008(22):349-69.
Almakhzangy I, Gaballa A. Serum level of IL-17, IL-22, IFN-γ in patients
with psoriasis. Egyptian Dermatology Online Journal 2009;5(1): 1-7.
Ragab MH,Maksoud NA, Roaiah M.Biochemical significance of pro
inflammatory cytokines in psoriasis vulgaris among Egyptian patients.
Journal of American Science.2010;6(10):423-8.
Tesmer LA,Lundy SK,Sarkar S,Fox DA. Th17 cells in human disease.
Immunological reviews.2008 (223): 87-113.
Blauvelt A. New concepts in the pathogenesis and treatment of
psoriasis:key roles for IL-23, Il-17A and TGF-β1. Expert Rev
Dermatol.2007 (1):69-71.
Ortega C,Fernandez S, Carillo JM, Romero P, Molina IJ, Moreno IC,
Santamaria M. IL-17 producing CD8+ T lymphocytes from psoriasis skin
plaques are cytotoxic effector cells that secrete Th17-related cytokines.
Journal of Leukocyte Biology. 2009(86):435-42.
Griffiths CEM., Barker JNW.Pathogenesis and clinical features of
psoriasis, Lancet, 2007(370):263-71.
Arican O, Aral M, Sasmaz S, Gragil P. Serum levels of TNF-α, IFN-γ, IL6, IL-8, IL-12, IL-17 and IL-18 in patients with active psoriasis and
correlation with disease severity. Mediators of inflammation.2005(5):2739.
Gudjonsson JE, Elder JT. Psoriasis dalam Wolff K, Goldsmith LA, Katz
SI, Gilchrest BA, Paller AS, Leffell DJ, editor. Fitzpatrick’s dermatology
in general medicine. Edisi-8. New York: McGrawHill Incoorporate;
2012:197-231.
Traub M, Marshall K. Psoriasis-pathophysiology, conventional, and
alternative approaches to treatment. Alternative Medicine Review
2007(12):319-30.
Parisi R, Symmons DPM, Griffiths CEM, Ashcroft D. Global
epidemiology of psoriasis: a systematic review of incidence and
prevalence. The society for investigative Dermatology. 2013 (133) : 377 83.
Sanchez APG. Immunopathogenesis of psoriasis. An Bras Dermatol.
2010( 85):747-9.
Universitas Sumatera Utara
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
Jariwala SP. The role of dendritic cells in the immunopathogenesis of
psoriasis. Arch Dermatol Res. 2007( 299):359-66.
Krueger G, Ellis CN. Psoriasis-recent advances in understanding its
pathogenesis and treatment. J.Am.Acad.Dermatol.2005(53):94-100.
Nestle FO, Kaplan DH, Barker,J.Psoriasis.N Engl J Med.2009(361):496509.
Coimbra S, Oliveira H, Figueiredo A, Rocha-Pereira P, Santos-silva A.
Psoriasis: Epidemiology, clinical and histological features, triggering
factors, assessment of severity and psychosocial aspects. IntechopenJ.
2004 (3):69-82.
Smith CH, Barker JNWN. Psoriasis and its management. BMJ.2006 (333):
380-4.
Miossec P, Korn T, Kuchroo V. Interleukin-17 and Type 17 helper T cells.
N Engl J Med 2009(361): 888-98.
Wynn TA. Th17: a giant step from Th1 and Th2. Nature Immunology.
2005(6):1069-70.
Romagnani S. Human Th17 cells. Arthritis Research&therapy
2008(10):206.
Mesquita D, Cruvinel WM, Camara NOS, Kallas EG, Andrade LEC.
Autoimmune diseases in the Th7 era. Braz J Med Biol Res.2009(42):47686.
Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL,
Kuchroo VK. Reciprocal developmental pathways for the generation of
pathogenic effector Th17 and regulatory T cells. Nature.2006 (44 ): 235-8.
Chung Y, Yang X, Chang SH. Expression and regulation of IL-22 in the
IL-17 producing CD4+T lymphocytes. Cell Research 2006(16): 902-7.
Langrish CL, Blumenschein WM, Mattson J, Basham B, Sedgwick JD,
McClanahan T, Kastelein RA, Cua DJ. IL-23 drives a pathogenic T cell
population that induces autoimmune inflammation. JEM. 2004(201): 23340.
Kramer JM, Gaffen SL. Interleukin-17: a new paradigm in inflammation,
autoimmunity and therapy. Review. J Periodontol. 2007(78): 1083-90.
Witowski J, Ksiazek K, Jurres A. Interleukin-17: a mediator of
inflammatory responses. CMLS Cell Mol Life Sci.2004(61):567-79.
Gaffen SL, An overview of IL-17 function and signaling. Cytokine
2008(3): 402-7.
Waite JC, Skokos D. Th17 response and inflammatory autoimmune
diseases. International Journal of Inflammation. 2012(212):1-7.
Manel N, Unutmaz D, Littman DR. The differentiation of human Th17
cells requires transforming growth factor-β and induction of the nuclear
receptor RORγt. Nature Immunology.2008(9): 641-7.
Korn T, Oukka M, Kuchroo V, Bettelli E. Th17 cells: effector T cells with
inflammatory properties. Semin Immunol. 2007(19):362-71.
Louten J, Boniface K, Malefyt RW. Development and function of Th17
cells in health and disease. J Allergy Clin Ummunol. 2009:1004-9.
Universitas Sumatera Utara
35.
36.
37.
38.
39.
40.
41.
Lowes MA, Kikuchi T, Fuentes-Duculan J, Cardinale I, Zaba LS, Haider
AS, Boman EP, Krueger JG. Psoriasis vulgaris lesions contain discrete
ppulations of Th1 and Th17 T cells. Journal of investigative Dermatology.
2008(128):1207-11.
Meglio PD, Nestle FO. The role of IL-23 in the immunopathogenesis of
psoriasis. Biology reports. 2010 (2): 1-5.
Meier M., Sheth PB. Clinical spectrum and severity of psoriasis. Curr
Probl Dermatol. Basel, Karger. 2009 (38):1-20.
Luo q., Zhang X., Luo Y., Lin L., Li J., Zhang S., Liu Y. Increased
expression of Th17 cytokines in patients with psoriasis. African Journal of
Biotechnology. 2012 (11):3413-5.
Sinniah B, Devi S, Prashant D. Epidemiology of Psoriasis in Malaysia: A
Hospital Based Study.Med J Malaysia.2010 (2):112-14.
Chandran V, Raychaudhuri SP. Geoepidemiology and environmental
factors of psoriasis and psoriatic arthritis. Journal of autoimmunity. 2010
(34):314-21.
Flatz L, Conrad C. Role of T-cell-mediated inflammation in psoriasis
pathogenesis and targeted therapy. Review. Psoriasis Targets and Therapy.
2013(3):1-10.
Universitas Sumatera Utara
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
MacDonald A, Burden AD. Psoriasis: advances in pathophysiology and
management. Postgrad Med J. 2007(83): 690-7.
Neimann AL, Porter SB, Gelfand JM. The epidemiology of psoriasis.
Expert Rev. Dermatol. 2006(1): 63-75.
Gudjonsson JE, Johnston A, Sigmundsdottir H, Valdimarsson H.
Immunopathogenic mechanism in psoriasis. Clin Exp Immunol.
2004(135):1-8.
Lowes MA, Lew W, Krueger JG. Current concepts in the
immunopathogenesis of psoriasis. Dermatol Clin.2008(22):349-69.
Almakhzangy I, Gaballa A. Serum level of IL-17, IL-22, IFN-γ in patients
with psoriasis. Egyptian Dermatology Online Journal 2009;5(1): 1-7.
Ragab MH,Maksoud NA, Roaiah M.Biochemical significance of pro
inflammatory cytokines in psoriasis vulgaris among Egyptian patients.
Journal of American Science.2010;6(10):423-8.
Tesmer LA,Lundy SK,Sarkar S,Fox DA. Th17 cells in human disease.
Immunological reviews.2008 (223): 87-113.
Blauvelt A. New concepts in the pathogenesis and treatment of
psoriasis:key roles for IL-23, Il-17A and TGF-β1. Expert Rev
Dermatol.2007 (1):69-71.
Ortega C,Fernandez S, Carillo JM, Romero P, Molina IJ, Moreno IC,
Santamaria M. IL-17 producing CD8+ T lymphocytes from psoriasis skin
plaques are cytotoxic effector cells that secrete Th17-related cytokines.
Journal of Leukocyte Biology. 2009(86):435-42.
Griffiths CEM., Barker JNW.Pathogenesis and clinical features of
psoriasis, Lancet, 2007(370):263-71.
Arican O, Aral M, Sasmaz S, Gragil P. Serum levels of TNF-α, IFN-γ, IL6, IL-8, IL-12, IL-17 and IL-18 in patients with active psoriasis and
correlation with disease severity. Mediators of inflammation.2005(5):2739.
Gudjonsson JE, Elder JT. Psoriasis dalam Wolff K, Goldsmith LA, Katz
SI, Gilchrest BA, Paller AS, Leffell DJ, editor. Fitzpatrick’s dermatology
in general medicine. Edisi-8. New York: McGrawHill Incoorporate;
2012:197-231.
Traub M, Marshall K. Psoriasis-pathophysiology, conventional, and
alternative approaches to treatment. Alternative Medicine Review
2007(12):319-30.
Parisi R, Symmons DPM, Griffiths CEM, Ashcroft D. Global
epidemiology of psoriasis: a systematic review of incidence and
prevalence. The society for investigative Dermatology. 2013 (133) : 377 83.
Sanchez APG. Immunopathogenesis of psoriasis. An Bras Dermatol.
2010( 85):747-9.
Universitas Sumatera Utara
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
Jariwala SP. The role of dendritic cells in the immunopathogenesis of
psoriasis. Arch Dermatol Res. 2007( 299):359-66.
Krueger G, Ellis CN. Psoriasis-recent advances in understanding its
pathogenesis and treatment. J.Am.Acad.Dermatol.2005(53):94-100.
Nestle FO, Kaplan DH, Barker,J.Psoriasis.N Engl J Med.2009(361):496509.
Coimbra S, Oliveira H, Figueiredo A, Rocha-Pereira P, Santos-silva A.
Psoriasis: Epidemiology, clinical and histological features, triggering
factors, assessment of severity and psychosocial aspects. IntechopenJ.
2004 (3):69-82.
Smith CH, Barker JNWN. Psoriasis and its management. BMJ.2006 (333):
380-4.
Miossec P, Korn T, Kuchroo V. Interleukin-17 and Type 17 helper T cells.
N Engl J Med 2009(361): 888-98.
Wynn TA. Th17: a giant step from Th1 and Th2. Nature Immunology.
2005(6):1069-70.
Romagnani S. Human Th17 cells. Arthritis Research&therapy
2008(10):206.
Mesquita D, Cruvinel WM, Camara NOS, Kallas EG, Andrade LEC.
Autoimmune diseases in the Th7 era. Braz J Med Biol Res.2009(42):47686.
Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL,
Kuchroo VK. Reciprocal developmental pathways for the generation of
pathogenic effector Th17 and regulatory T cells. Nature.2006 (44 ): 235-8.
Chung Y, Yang X, Chang SH. Expression and regulation of IL-22 in the
IL-17 producing CD4+T lymphocytes. Cell Research 2006(16): 902-7.
Langrish CL, Blumenschein WM, Mattson J, Basham B, Sedgwick JD,
McClanahan T, Kastelein RA, Cua DJ. IL-23 drives a pathogenic T cell
population that induces autoimmune inflammation. JEM. 2004(201): 23340.
Kramer JM, Gaffen SL. Interleukin-17: a new paradigm in inflammation,
autoimmunity and therapy. Review. J Periodontol. 2007(78): 1083-90.
Witowski J, Ksiazek K, Jurres A. Interleukin-17: a mediator of
inflammatory responses. CMLS Cell Mol Life Sci.2004(61):567-79.
Gaffen SL, An overview of IL-17 function and signaling. Cytokine
2008(3): 402-7.
Waite JC, Skokos D. Th17 response and inflammatory autoimmune
diseases. International Journal of Inflammation. 2012(212):1-7.
Manel N, Unutmaz D, Littman DR. The differentiation of human Th17
cells requires transforming growth factor-β and induction of the nuclear
receptor RORγt. Nature Immunology.2008(9): 641-7.
Korn T, Oukka M, Kuchroo V, Bettelli E. Th17 cells: effector T cells with
inflammatory properties. Semin Immunol. 2007(19):362-71.
Louten J, Boniface K, Malefyt RW. Development and function of Th17
cells in health and disease. J Allergy Clin Ummunol. 2009:1004-9.
Universitas Sumatera Utara
35.
36.
37.
38.
39.
40.
41.
Lowes MA, Kikuchi T, Fuentes-Duculan J, Cardinale I, Zaba LS, Haider
AS, Boman EP, Krueger JG. Psoriasis vulgaris lesions contain discrete
ppulations of Th1 and Th17 T cells. Journal of investigative Dermatology.
2008(128):1207-11.
Meglio PD, Nestle FO. The role of IL-23 in the immunopathogenesis of
psoriasis. Biology reports. 2010 (2): 1-5.
Meier M., Sheth PB. Clinical spectrum and severity of psoriasis. Curr
Probl Dermatol. Basel, Karger. 2009 (38):1-20.
Luo q., Zhang X., Luo Y., Lin L., Li J., Zhang S., Liu Y. Increased
expression of Th17 cytokines in patients with psoriasis. African Journal of
Biotechnology. 2012 (11):3413-5.
Sinniah B, Devi S, Prashant D. Epidemiology of Psoriasis in Malaysia: A
Hospital Based Study.Med J Malaysia.2010 (2):112-14.
Chandran V, Raychaudhuri SP. Geoepidemiology and environmental
factors of psoriasis and psoriatic arthritis. Journal of autoimmunity. 2010
(34):314-21.
Flatz L, Conrad C. Role of T-cell-mediated inflammation in psoriasis
pathogenesis and targeted therapy. Review. Psoriasis Targets and Therapy.
2013(3):1-10.
Universitas Sumatera Utara